Company Filing History:
Years Active: 2023-2024
Title: Innovations of Huiqin Guo in Biopharmaceuticals
Introduction
Huiqin Guo is a notable inventor based in Shanghai, China, recognized for his contributions to the field of biopharmaceuticals. He has been instrumental in developing innovative antibodies that target specific proteins associated with various diseases. His work has led to significant advancements in therapeutic approaches.
Latest Patents
Huiqin Guo holds two recent patents that showcase his expertise. The first patent is titled "Antibodies binding CD24, preparation and use thereof." This patent discloses an antibody that specifically binds to CD24, along with a nucleic acid molecule encoding the antibody. It also includes methods for expressing the antibody and treating diseases associated with CD24 signaling. The second patent is "Antibodies binding CD70, preparation and use thereof." This patent similarly describes an antibody that binds to CD70 and provides details on the nucleic acid molecule, expression vector, and methods for treatment related to CD70 signaling.
Career Highlights
Huiqin Guo is currently associated with Immuneonco Biopharmaceuticals (Shanghai) Inc., where he continues to innovate in the field of antibody development. His work is pivotal in advancing therapeutic options for diseases linked to CD24 and CD70.
Collaborations
Huiqin Guo collaborates with talented professionals in his field, including Wenzhi Tian and Song Li. Their combined expertise contributes to the success of their projects and the advancement of biopharmaceutical research.
Conclusion
Huiqin Guo's innovative work in developing antibodies for CD24 and CD70 has the potential to transform treatment options for various diseases. His contributions to Immuneonco Biopharmaceuticals highlight the importance of collaboration and innovation in the biopharmaceutical industry.